Demecan

About Demecan

Demecan operates as a key German enterprise in the medical cannabis sector, uniquely positioned as a domestic producer with a vertically integrated model. Founded in 2017 by Dr. Adrian Fischer (a physician), Dr. Constantin von der Groeben (a lawyer), and Dr. Cornelius Maurer (an economist), the company was established in response to the 2017 "Cannabis as Medicine Act" in Germany. The founders' diverse backgrounds in medicine, law, and economics provided a comprehensive foundation to navigate the complex regulatory and business landscape of the nascent German medical cannabis market.

The company's core business encompasses the entire value chain: cultivation, processing, storage, and distribution of medical-grade cannabis products. It operates on a B2B model, selling its products directly to pharmacies across Germany to fulfill patient prescriptions. In May 2019, Demecan was one of only three companies, and the sole German-owned entity, to be awarded a contract by Germany's Federal Institute for Drugs and Medical Devices (BfArM) to cultivate and distribute medical cannabis. This solidified its position as a government-sanctioned producer. The firm's product line includes dried cannabis flowers and extracts, all manufactured under stringent EU-GMP (Good Manufacturing Practice) standards, ensuring pharmaceutical quality and safety.

A significant milestone was the commissioning of its EU-GMP certified production facility near Dresden, Saxony, considered Europe's largest indoor cultivation site for medical cannabis. First harvests began in late 2021, with deliveries to pharmacies starting in early 2022. In July 2024, Demecan became the first German company to receive a cultivation license under the new Medical Cannabis Law (MedCanG), allowing it to significantly increase production capacity to meet growing demand. The company also functions as a wholesaler, importing products from international partners to supplement its domestic supply and broaden its portfolio. Revenue is generated through the sale of these domestically cultivated and imported cannabis products to pharmacies. Demecan has successfully raised capital through multiple funding rounds, including a Series A of €7 million in 2019 and a Series B in August 2024, to fuel expansion and research.